These findings suggest that pharmacological intervention aimed at GJs‐Cx43, the critical control point of oxidative stress and neuroinflammation, may hold therapeutic promise for cognitive decline in many CNS diseases. This evidence concerns the gene GJA1 and Mental deterioration.